Apraglutide (FE 203799), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum[1].

In Vivo
Apraglutide (FE 203799; 5 mg/kg/dose, subcutaneously, twice on days 0 and 4 postsurgery) treated piglets are healthy, have significant lower fecal fat and energy losses and exhibit intestinal lengthening, greater small-intestinal weight, longer villus height, and greater crypt depth on day 7[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Newborn Duroc piglets, 2–5 days old and weighing between 2-2.6 kg[1].
Dosage: 5 mg/kg/dose.
Administration: Subcutaneously, twice on days 0 and 4 postsurgery.
Result: On day 7, treated piglets were healthy, had significant lower fecal fat and energy losses and exhibited intestinal lengthening, greater small-intestinal weight, longer villus height, and greater crypt depth.

REFERENCES
Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898  Fax: 609-228-5909  E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA